CCL7/MCP-3/MARC Antibody

Recombinant Human CCL7/MCP‑3 (Catalog # 282-P3) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR2A in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL7/MCP‑3 (1 µg/mL) is neutralized (green line) by increasing concentrations of Human CCL7/MCP‑3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-282-NA). The ND50 is typically 10-30 µg/mL.

• Reactivity: Hu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

CCL7/MCP-3/MARC Antibody Summary

• Immunogen: E. coli-derived recombinant human CCL7/MCP‑3/MARC (R&D Systems, Catalog # 282-P3)
  Gln34-Leu109
  Accession # Q7Z7Q8
• Specificity: Detects human CCL7/MCP-3/MARC in direct ELISAs and Western blots. In these formats, less than 20% cross-reactivity with recombinant human (rh) Eotaxin is observed and less than 5% cross-reactivity with rhMCP-2, rhMCP-1, and recombinant mouse JE is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CCL7
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 10-30 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL7/MCP-3/MARC Antibody

• C-C motif chemokine 7
• CCL7
• chemokine (C-C motif) ligand 7
• FIC
• MARC
• MCP-3
• MCP3Monocyte chemotactic protein 3
• MCP-3Small-inducible cytokine A7
• MGC138465
• Monocyte chemoattractant protein 3
• NC28SCYA6
• SCYA7MGC138463
• small inducible cytokine A7 (monocyte chemotactic protein 3)

Background

MCP-2 and CCL7 are two monocyte chemotactic proteins produced by human MG-63 osteosarcoma cells. Both MCP-2 and CCL7 are members of the C-C family of chemokines and share 62% and 71% amino acid sequence identity, respectively, with MCP-1. CCL7 also shares 58% amino acid identity with MCP-2. CCL7 cDNA encodes a 99 amino acid residue precursor protein from which the N-terminal 23 amino acid residues are cleaved to generate the 76 amino acid residue mature CCL7. Mature CCL7 contains a potential N-linked and several possible O-linked glycosylation sites. Similar to other C-C chemokines, all three MCP proteins are monocyte chemoattractants. In addition, the three MCPs can chemoattract activated NK cells as well as CD4 + and CD8 + T lymphocytes. All three cytokines have also been shown to attract eosinophils and induce histamine secretion from basophils.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CCL7/MCP-3/MARC Antibody (AF-282-NA)(1)

Publication using AF-282-NA

• Evidence for chemokine synergy during neutrophil migration in ARDS Thorax, 2016-08-05;0(0):. 2016-08-05 [PMID: 27496101] (Neutralization, Human)

Bioinformatics

• Gene Symbol: CCL7
• Uniprot:
  • Q7Z7Q8()